JP2001500475A - 細胞接着を調節するための化合物および方法 - Google Patents

細胞接着を調節するための化合物および方法

Info

Publication number
JP2001500475A
JP2001500475A JP10505472A JP50547298A JP2001500475A JP 2001500475 A JP2001500475 A JP 2001500475A JP 10505472 A JP10505472 A JP 10505472A JP 50547298 A JP50547298 A JP 50547298A JP 2001500475 A JP2001500475 A JP 2001500475A
Authority
JP
Japan
Prior art keywords
cyclic peptide
cadherin
cells
mammal
cell adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10505472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001500475A5 (enExample
Inventor
ダブリュー． ブラシューク，オレスト
ジョーン グール，バーバラ
Original Assignee
マクギル ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マクギル ユニバーシティ filed Critical マクギル ユニバーシティ
Publication of JP2001500475A publication Critical patent/JP2001500475A/ja
Publication of JP2001500475A5 publication Critical patent/JP2001500475A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP10505472A 1996-07-12 1997-07-11 細胞接着を調節するための化合物および方法 Pending JP2001500475A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2161296P 1996-07-12 1996-07-12
US60/021,612 1996-07-12
PCT/CA1997/000489 WO1998002452A2 (en) 1996-07-12 1997-07-11 Compounds and methods for modulating cell adhesion

Publications (2)

Publication Number Publication Date
JP2001500475A true JP2001500475A (ja) 2001-01-16
JP2001500475A5 JP2001500475A5 (enExample) 2005-03-10

Family

ID=21805187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10505472A Pending JP2001500475A (ja) 1996-07-12 1997-07-11 細胞接着を調節するための化合物および方法

Country Status (8)

Country Link
US (3) US6031072A (enExample)
EP (1) EP0937103B1 (enExample)
JP (1) JP2001500475A (enExample)
AU (1) AU722985B2 (enExample)
CA (1) CA2259966A1 (enExample)
DE (1) DE69738326T2 (enExample)
ES (1) ES2297861T3 (enExample)
WO (1) WO1998002452A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018503609A (ja) * 2014-12-19 2018-02-08 ニューロ−バイオ リミテッドＮｅｕｒｏ−Ｂｉｏ Ｌｔｄ 癌または転移性疾患の治療または予防における環状アセチルコリンエステラーゼｃ末端ペプチド
JP2021525077A (ja) * 2018-05-23 2021-09-24 キュアバイオ カンパニー リミテッド 断片化されたｇｒｓポリペプチド、その変異体及びこれらの用途
WO2022098051A1 (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
JP2022544640A (ja) * 2019-06-21 2022-10-20 ユニバーシティ オブ カンザス 脳疾患の治療に有用な組成物および方法

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333307B1 (en) * 1996-07-12 2001-12-25 Mcgill University Compounds and method for modulating neurite outgrowth
US6169071B1 (en) * 1996-07-12 2001-01-02 Mcgill University Compounds and methods for modulating cell adhesion
US6562786B1 (en) 1996-07-12 2003-05-13 Mcgill University Compounds and methods for modulating apoptosis
WO1998002452A2 (en) 1996-07-12 1998-01-22 Mcgill University Compounds and methods for modulating cell adhesion
US6207639B1 (en) * 1996-07-12 2001-03-27 Mcgill University Compounds and methods for modulating neurite outgrowth
US6346512B1 (en) * 1996-07-12 2002-02-12 Mcgill University Compounds and methods for modulating cell adhesion
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
US6417325B1 (en) * 1996-07-12 2002-07-09 Mcgill University Compounds and methods for cancer therapy
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6610821B1 (en) * 1996-07-12 2003-08-26 Mcgill University Compounds and methods for modulating endothelial cell adhesion
US20020168761A1 (en) * 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6465427B1 (en) 1996-07-12 2002-10-15 Mcgill University Compounds and methods for modulating cell adhesion
US6551994B1 (en) * 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US20050203025A1 (en) * 1998-05-05 2005-09-15 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6638911B1 (en) * 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US7481999B2 (en) * 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
EP1075494A2 (en) * 1998-05-05 2001-02-14 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
WO2000001418A1 (en) 1998-07-02 2000-01-13 Genzyme Corporation Transgene expression in polarized cells
US6277824B1 (en) 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
AU4417000A (en) * 1999-04-15 2000-11-02 Glaxo Group Limited Novel pharmaceutical composition suitable for gene therapy
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
US20040254099A1 (en) * 1999-04-21 2004-12-16 Adherex Technologies, Inc. Compounds and methods for modulating beta-catenin mediated gene expression
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
AU2002226075A1 (en) * 2000-10-23 2002-05-06 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
US6815426B2 (en) * 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
US20020192206A1 (en) * 2001-05-05 2002-12-19 Kozarov Emil V. Methods and compositions for angioproliferative disorder treatment
US20030105025A1 (en) * 2001-10-31 2003-06-05 Fortuna Haviv Tri-and tetrapeptides having antiangiogenic activity
US7175990B2 (en) * 2002-02-26 2007-02-13 The Regents Of The University Of California Method of determining endometrial receptivity
CA2504768A1 (en) * 2002-11-14 2004-05-27 Adherex Technologies, Inc. Compounds and methods for modulating functions of classical cadherins
US7476509B2 (en) * 2002-11-14 2009-01-13 Adherex Technologies Inc. Compounds and methods for modulating functions of nonclassical cadherins
US7196061B2 (en) 2003-09-10 2007-03-27 Wyeth Compounds that modulate neuronal growth and their uses
US7816353B2 (en) * 2003-10-24 2010-10-19 Exelixis, Inc. P70S6 kinase modulators and method of use
WO2005097112A2 (en) * 2004-03-08 2005-10-20 Wyeth Ion channel modulators
US7169756B2 (en) * 2004-04-16 2007-01-30 Mcmaster University Streptogramin antibiotics
EP1877444A2 (en) * 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
JP2009510105A (ja) 2005-09-28 2009-03-12 バイオバスキュラー インコーポレーティッド 血小板および細胞の接着、細胞移動、および炎症を阻止するための方法および組成物
US20110034396A1 (en) * 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
WO2007133746A2 (en) * 2006-05-15 2007-11-22 Biogen Idec Ma Inc. Use of nogo receptor-1 (ngr1) antagonists for promoting oligodendrocyte survival
WO2008039525A2 (en) * 2006-09-27 2008-04-03 Adherex Technologies, Inc. Cadherin antagonists in combination with anticancer agents for use in cancer treatment
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
US20090291967A1 (en) * 2008-03-05 2009-11-26 Adherex Technologies, Inc. Small molecule modulators of cell adhesion
US9599603B2 (en) * 2008-07-16 2017-03-21 Case Western Reserve University Methods and compositions for modulating adhesion and migration of cadherin expressing cells
EP2376100B1 (en) 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8680150B2 (en) 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
CA2774973A1 (en) * 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
FR2980741B1 (fr) 2011-09-30 2014-03-14 Saint Gobain Procede d'assemblage par collage d'un vitrage sur un support avec interposition d'une cale d'ecartement, vitrage muni d'une cale d'ecartement, cale, cordon profile et ensemble de cales.
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
JP2016520592A (ja) 2013-05-24 2016-07-14 タリックス ファーマシューティカルズ リミテッド マルファン症候群および関連障害の処置におけるアンジオテンシンペプチド
MX2016004660A (es) 2013-10-11 2016-11-14 Tarix Pharmaceuticals Ltd Composiciones de peptido novedosas.
EP3074417A4 (en) 2013-11-25 2017-05-03 Unm.Stc Cxcr antagonistic peptides and uses thereof
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
WO2016097753A1 (en) * 2014-12-19 2016-06-23 Neuro-Bio Ltd Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10960045B2 (en) 2015-10-14 2021-03-30 Constant Therapeutics Llc Methods and compositions for the treatment of epidermolysis bullosa
WO2021183863A1 (en) 2020-03-13 2021-09-16 Constant Therapeutics Llc Methods and compositions for treatment of coronavirus infection
CN116535406B (zh) * 2022-01-25 2025-06-24 中国科学院大连化学物理研究所 一种多萜衍生物的对映选择性合成方法及多萜衍生物
CN116535281B (zh) * 2022-01-25 2025-06-24 中国科学院大连化学物理研究所 一种手性环状单萜衍生物及其合成方法
WO2025122594A1 (en) 2023-12-04 2025-06-12 Constant Therapeutics, Llc Improved methods and compositions for the treatment of pemphigus or pemphigoid disease
TW202541831A (zh) 2023-12-21 2025-11-01 美商康斯坦特治療有限責任公司 治療視神經病變之方法及組合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079600A (en) * 1987-03-06 1992-01-07 Schnur Joel M High resolution patterning on solid substrates
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5231082A (en) * 1989-05-10 1993-07-27 Monsanto Company Cyclic peptide with anti-metastasis activity
WO1991004745A1 (en) * 1989-09-27 1991-04-18 Athena Neurosciences, Inc. Compositions for cell adhesion inhibition and methods of use
WO1992008731A2 (en) * 1990-10-30 1992-05-29 La Jolla Cancer Research Foundation T-cadherin adhesion molecule
JPH07503944A (ja) * 1991-11-22 1995-04-27 イエダ　リサーチ　アンド　デベロツプメント　カンパニー　リミテツド Ａｒｇ−ｇｌｙ−ａｓｐ配列の非ペプチド代替物およびそれらからなる医薬組成物
US5646250A (en) 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
WO1994011401A1 (en) 1992-11-17 1994-05-26 Yale University Human homolog of the e-cadherin gene and methods based thereon
US5591432A (en) * 1993-02-17 1997-01-07 Becton, Dickinson And Company Antibody to the neural cell adhesion molecule and methods of use
US5665590A (en) * 1994-07-29 1997-09-09 Systemix, Inc. Method for isolating and directly cloning genes which encode cell-surface and secreted proteins
WO1996040781A1 (en) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
GB9517098D0 (en) * 1995-08-21 1995-10-25 Imperial College Receptor
US6169071B1 (en) 1996-07-12 2001-01-02 Mcgill University Compounds and methods for modulating cell adhesion
WO1998002452A2 (en) 1996-07-12 1998-01-22 Mcgill University Compounds and methods for modulating cell adhesion
US6551994B1 (en) 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018503609A (ja) * 2014-12-19 2018-02-08 ニューロ−バイオ リミテッドＮｅｕｒｏ−Ｂｉｏ Ｌｔｄ 癌または転移性疾患の治療または予防における環状アセチルコリンエステラーゼｃ末端ペプチド
JP7066409B2 (ja) 2014-12-19 2022-05-13 ニューロ－バイオ リミテッド 癌または転移性疾患の治療または予防における環状アセチルコリンエステラーゼｃ末端ペプチド
JP2021525077A (ja) * 2018-05-23 2021-09-24 キュアバイオ カンパニー リミテッド 断片化されたｇｒｓポリペプチド、その変異体及びこれらの用途
JP2022544640A (ja) * 2019-06-21 2022-10-20 ユニバーシティ オブ カンザス 脳疾患の治療に有用な組成物および方法
WO2022098051A1 (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
KR20220061018A (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
KR102911194B1 (ko) * 2020-11-05 2026-01-13 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드

Also Published As

Publication number Publication date
DE69738326D1 (de) 2008-01-10
ES2297861T3 (es) 2008-05-01
US6326352B1 (en) 2001-12-04
AU722985B2 (en) 2000-08-17
CA2259966A1 (en) 1998-01-22
WO1998002452A3 (en) 1998-03-05
WO1998002452A2 (en) 1998-01-22
DE69738326T2 (de) 2008-07-03
US20020151475A1 (en) 2002-10-17
EP0937103A2 (en) 1999-08-25
US6031072A (en) 2000-02-29
EP0937103B1 (en) 2007-11-28
US6914044B2 (en) 2005-07-05
AU3332297A (en) 1998-02-09

Similar Documents

Publication Publication Date Title
AU722985B2 (en) Compounds and methods for modulating cell adhesion
US6169071B1 (en) Compounds and methods for modulating cell adhesion
US6310177B1 (en) Compounds and methods for modulating tissue permeability
US6472368B1 (en) Compounds and methods for modulating adhesion molecule function
US7122623B2 (en) Compounds and methods for modulating cell adhesion
US6551994B1 (en) Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
JP2003524384A (ja) クラウディン媒介機能を調節するための化合物および方法
US7326686B2 (en) Compounds and methods for regulating cell adhesion
US6465427B1 (en) Compounds and methods for modulating cell adhesion
US6610821B1 (en) Compounds and methods for modulating endothelial cell adhesion
US6346512B1 (en) Compounds and methods for modulating cell adhesion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080423

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080624

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090630